2017 Q4 Form 10-K Financial Statement

#000119312518060951 Filed on February 27, 2018

View on sec.gov

Income Statement

Concept 2017 Q4 2017 Q3 2017 Q2
Revenue $10.05M $8.572M $8.510M
YoY Change 686.0%
Cost Of Revenue $1.338M $1.051M $1.013M
YoY Change 3722.86%
Gross Profit $8.715M $7.521M $7.497M
YoY Change 600.56%
Gross Profit Margin 86.69% 87.74% 88.1%
Selling, General & Admin $22.85M $19.99M $20.96M
YoY Change 23.22% 14.29% 32.79%
% of Gross Profit 262.17% 265.8% 279.51%
Research & Development $47.76M $28.84M $28.60M
YoY Change 61.86% -4.62% 4.8%
% of Gross Profit 547.99% 383.51% 381.45%
Depreciation & Amortization $380.0K $410.0K $410.0K
YoY Change 22.58% 36.67% 64.0%
% of Gross Profit 4.36% 5.45% 5.47%
Operating Expenses $70.61M $49.89M $50.57M
YoY Change 46.95% 4.51% 17.41%
Operating Profit -$61.89M -$41.31M -$42.06M
YoY Change 32.24% -13.45% -2.35%
Interest Expense -$560.0K -$552.0K -$744.0K
YoY Change -144.09% -162.3% -389.49%
% of Operating Profit
Other Income/Expense, Net -$600.0K -$552.0K -$744.0K
YoY Change -48.28% -28.77% 365.0%
Pretax Income -$62.49M -$41.87M -$42.80M
YoY Change 30.3% -13.69% -0.99%
Income Tax $0.00
% Of Pretax Income
Net Earnings -$62.49M -$41.87M -$42.80M
YoY Change 30.29% -13.69% -0.99%
Net Earnings / Revenue -621.61% -488.4% -502.93%
Basic Earnings Per Share
Diluted Earnings Per Share -$1.085M -$772.8K -$795.7K
COMMON SHARES
Basic Shares Outstanding
Diluted Shares Outstanding

Balance Sheet

Concept 2017 Q4 2017 Q3 2017 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $172.4M $74.00M $109.3M
YoY Change 237.38% -16.76% 46.51%
Cash & Equivalents $144.6M $65.52M $30.28M
Short-Term Investments $27.80M $8.500M $79.00M
Other Short-Term Assets $3.700M $4.600M $3.700M
YoY Change 0.0% 48.39% 15.63%
Inventory $10.11M $5.169M $4.801M
Prepaid Expenses
Receivables $41.87M $28.85M $18.62M
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $228.1M $112.6M $136.4M
YoY Change 267.0% 19.81% 68.07%
LONG-TERM ASSETS
Property, Plant & Equipment $5.981M $5.343M $5.754M
YoY Change 17.83% 13.63% 28.7%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $263.0K $263.0K $263.0K
YoY Change 0.0% 102.31% 102.31%
Total Long-Term Assets $6.244M $5.606M $6.017M
YoY Change 16.95% 16.02% 30.78%
TOTAL ASSETS
Total Short-Term Assets $228.1M $112.6M $136.4M
Total Long-Term Assets $6.244M $5.606M $6.017M
Total Assets $234.3M $118.2M $142.4M
YoY Change 247.21% 19.62% 66.07%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $18.77M $5.337M $6.315M
YoY Change 175.45% -12.36% -27.09%
Accrued Expenses $53.00M $38.80M $33.90M
YoY Change 89.96% 75.57% 102.99%
Deferred Revenue $2.763M
YoY Change
Short-Term Debt $3.700M $3.500M $3.300M
YoY Change
Long-Term Debt Due $25.00M
YoY Change 762.07%
Total Short-Term Liabilities $103.2M $53.14M $48.30M
YoY Change 166.36% 71.84% 73.16%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $25.00M $25.00M
YoY Change -100.0% -50.0%
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $0.00 $25.00M $25.00M
YoY Change -100.0% -50.0%
TOTAL LIABILITIES
Total Short-Term Liabilities $103.2M $53.14M $48.30M
Total Long-Term Liabilities $0.00 $25.00M $25.00M
Total Liabilities $103.2M $78.14M $73.30M
YoY Change 16.27% -3.44% 162.71%
SHAREHOLDERS EQUITY
Retained Earnings -$783.5M -$721.0M -$679.1M
YoY Change 33.7% 34.01% 38.73%
Common Stock $646.0K $546.0K $539.0K
YoY Change 63.96% 39.64% 38.21%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $131.1M $40.05M $69.08M
YoY Change
Total Liabilities & Shareholders Equity $234.3M $118.2M $142.4M
YoY Change 247.21% 19.62% 66.07%

Cashflow Statement

Concept 2017 Q4 2017 Q3 2017 Q2
OPERATING ACTIVITIES
Net Income -$62.49M -$41.87M -$42.80M
YoY Change 30.29% -13.69% -0.99%
Depreciation, Depletion And Amortization $380.0K $410.0K $410.0K
YoY Change 22.58% 36.67% 64.0%
Cash From Operating Activities -$47.15M -$40.54M -$32.03M
YoY Change 22.4% 12.24% 18.15%
INVESTING ACTIVITIES
Capital Expenditures -$1.130M $0.00 -$480.0K
YoY Change 63.77% -100.0% -55.56%
Acquisitions
YoY Change
Other Investing Activities -$19.23M $70.60M $2.900M
YoY Change -449.64% -330.57% -85.23%
Cash From Investing Activities -$20.36M $70.61M $2.410M
YoY Change -523.28% -326.68% -87.02%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $142.6M
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 146.6M 5.180M -23.62M
YoY Change 9736.91% -89.84% -1052.42%
NET CHANGE
Cash From Operating Activities -47.15M -40.54M -32.03M
Cash From Investing Activities -20.36M 70.61M 2.410M
Cash From Financing Activities 146.6M 5.180M -23.62M
Net Change In Cash 79.06M 35.25M -53.24M
YoY Change -345.38% -316.13% 777.1%
FREE CASH FLOW
Cash From Operating Activities -$47.15M -$40.54M -$32.03M
Capital Expenditures -$1.130M $0.00 -$480.0K
Free Cash Flow -$46.02M -$40.54M -$31.55M
YoY Change 21.65% 13.94% 21.21%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2016 hrtx Stock Issued During Period Value Warrants Exercised
StockIssuedDuringPeriodValueWarrantsExercised
CY2017 hrtx Stock Issued During Period Value Warrants Exercised
StockIssuedDuringPeriodValueWarrantsExercised
CY2017 hrtx Valuation Allowances And Reserves Provisions
ValuationAllowancesAndReservesProvisions
19252000
CY2017Q4 hrtx Accrued Clinical Liabilities
AccruedClinicalLiabilities
26920000
CY2016Q4 hrtx Accrued Clinical Liabilities
AccruedClinicalLiabilities
13207000
CY2017Q4 hrtx Accrued Sales Allowances Current
AccruedSalesAllowancesCurrent
9319000
CY2016Q4 hrtx Accrued Sales Allowances Current
AccruedSalesAllowancesCurrent
342000
CY2017Q4 hrtx Adjustment Of Deferred Tax Asset Liability Revaluation Based On New Tax Rate
AdjustmentOfDeferredTaxAssetLiabilityRevaluationBasedOnNewTaxRate
74300000
CY2017Q4 hrtx Common Stock Underlying Convertible Notes Outstanding
CommonStockUnderlyingConvertibleNotesOutstanding
7982957
CY2011Q2 hrtx Convertible Debt Issuable In Connection With Private Placement1
ConvertibleDebtIssuableInConnectionWithPrivatePlacement1
4500000
CY2017Q4 hrtx Convertible Notes Payable Related Parties Current
ConvertibleNotesPayableRelatedPartiesCurrent
3684000
CY2016Q4 hrtx Convertible Notes Payable Related Parties Current
ConvertibleNotesPayableRelatedPartiesCurrent
2911000
CY2017 hrtx Defined Contribution Plan Maximum Annual Contributions By Employer Per Employee Amount
DefinedContributionPlanMaximumAnnualContributionsByEmployerPerEmployeeAmount
8100
CY2016 hrtx Defined Contribution Plan Maximum Annual Contributions By Employer Per Employee Amount
DefinedContributionPlanMaximumAnnualContributionsByEmployerPerEmployeeAmount
7950
CY2015 hrtx Defined Contribution Plan Maximum Annual Contributions By Employer Per Employee Amount
DefinedContributionPlanMaximumAnnualContributionsByEmployerPerEmployeeAmount
7950
CY2017 hrtx Effective Income Tax Rate Reconciliation Nondeductible Expense Compensation Amount
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseCompensationAmount
CY2016 hrtx Effective Income Tax Rate Reconciliation Nondeductible Expense Compensation Amount
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseCompensationAmount
1864000
CY2015 hrtx Effective Income Tax Rate Reconciliation Nondeductible Expense Compensation Amount
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseCompensationAmount
CY2017Q4 hrtx Employee Stock Purchase Plan Available For Issuance
EmployeeStockPurchasePlanAvailableForIssuance
267317
CY2017 hrtx Increase Decrease In Clinical Liabilities
IncreaseDecreaseInClinicalLiabilities
13713000
CY2016 hrtx Increase Decrease In Clinical Liabilities
IncreaseDecreaseInClinicalLiabilities
7976000
CY2015 hrtx Increase Decrease In Clinical Liabilities
IncreaseDecreaseInClinicalLiabilities
1420000
CY2015 hrtx Stock Issued During Period Value Warrants Exercised
StockIssuedDuringPeriodValueWarrantsExercised
CY2017Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
18769000
CY2016Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
6814000
CY2017Q4 us-gaap Accounts Payable Other Current
AccountsPayableOtherCurrent
148000
CY2016Q4 us-gaap Accounts Payable Other Current
AccountsPayableOtherCurrent
1039000
CY2017Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
41874000
CY2016Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
1960000
CY2017 us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
278000
CY2016 us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-274000
CY2015 us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-89000
CY2017Q4 us-gaap Accrued Bonuses Current
AccruedBonusesCurrent
5044000
CY2016Q4 us-gaap Accrued Bonuses Current
AccruedBonusesCurrent
3474000
CY2017Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
6869000
CY2016Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
4703000
CY2017Q4 us-gaap Accrued Rent Current
AccruedRentCurrent
651000
CY2016Q4 us-gaap Accrued Rent Current
AccruedRentCurrent
116000
CY2017Q4 us-gaap Accrued Salaries Current
AccruedSalariesCurrent
2730000
CY2016Q4 us-gaap Accrued Salaries Current
AccruedSalariesCurrent
2236000
CY2017Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
7859000
CY2016Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
6614000
CY2017Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-10000
CY2016Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-17000
CY2017Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
913955000
CY2016Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
564343000
CY2015 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
14360000
CY2016 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
25956000
CY2017 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
30538000
CY2017 us-gaap Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
226000
CY2017 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
30538000
CY2016 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
25956000
CY2015 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
14360000
CY2017 us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
773000
CY2016 us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
689000
CY2015 us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
624000
CY2017 us-gaap Asset Impairment Charges
AssetImpairmentCharges
0
CY2016 us-gaap Asset Impairment Charges
AssetImpairmentCharges
0
CY2017Q4 us-gaap Assets
Assets
234307000
CY2016Q4 us-gaap Assets
Assets
67482000
CY2017Q4 us-gaap Assets Current
AssetsCurrent
228063000
CY2016Q4 us-gaap Assets Current
AssetsCurrent
62143000
CY2017Q4 us-gaap Available For Sale Securities Amortized Cost
AvailableForSaleSecuritiesAmortizedCost
27806000
CY2016Q4 us-gaap Available For Sale Securities Amortized Cost
AvailableForSaleSecuritiesAmortizedCost
37741000
CY2017Q4 us-gaap Available For Sale Securities Current
AvailableForSaleSecuritiesCurrent
27796000
CY2016Q4 us-gaap Available For Sale Securities Current
AvailableForSaleSecuritiesCurrent
37724000
CY2016Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
39355
CY2017 us-gaap Available For Sale Securities Gross Realized Gains
AvailableForSaleSecuritiesGrossRealizedGains
0
CY2016 us-gaap Available For Sale Securities Gross Realized Gains
AvailableForSaleSecuritiesGrossRealizedGains
0
CY2015 us-gaap Available For Sale Securities Gross Realized Gains
AvailableForSaleSecuritiesGrossRealizedGains
0
CY2017 us-gaap Available For Sale Securities Gross Realized Losses
AvailableForSaleSecuritiesGrossRealizedLosses
0
CY2016 us-gaap Available For Sale Securities Gross Realized Losses
AvailableForSaleSecuritiesGrossRealizedLosses
0
CY2015 us-gaap Available For Sale Securities Gross Realized Losses
AvailableForSaleSecuritiesGrossRealizedLosses
0
CY2017 us-gaap Available For Sale Securities Gross Unrealized Gains
AvailableForSaleSecuritiesGrossUnrealizedGains
7000
CY2016 us-gaap Available For Sale Securities Gross Unrealized Gains
AvailableForSaleSecuritiesGrossUnrealizedGains
23000
CY2015 us-gaap Available For Sale Securities Gross Unrealized Loss
AvailableForSaleSecuritiesGrossUnrealizedLoss
40000
CY2017 us-gaap Available For Sale Securities Gross Unrealized Loss
AvailableForSaleSecuritiesGrossUnrealizedLoss
10000
CY2016 us-gaap Available For Sale Securities Gross Unrealized Loss
AvailableForSaleSecuritiesGrossUnrealizedLoss
17000
CY2017Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
144583000
CY2016Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
13414000
CY2015Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
75180000
CY2014Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
72675000
CY2017 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
131169000
CY2016 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-61766000
CY2015 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
2505000
CY2017Q4 us-gaap Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
172400000
CY2017Q4 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
49400000
CY2017Q4 us-gaap Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
620164
CY2017Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2016Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2017Q4 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
27018833
CY2017Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2016Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2017Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000
CY2016Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000
CY2017Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
64609
CY2016Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
39355
CY2017Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
64609
CY2017Q4 us-gaap Common Stock Value
CommonStockValue
646000
CY2016Q4 us-gaap Common Stock Value
CommonStockValue
394000
CY2015 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-97631000
CY2016 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-173120000
CY2017 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-197477000
CY2017 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:left;"><div style="display: inline; font-style: italic;"><div style="display: inline; font-weight: bold;">Concentration of Credit Risk</div></div></div> <div style=" font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</div> <div style=" font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">Cash, <div style="display: inline; font-family:Times New Roman, Times, serif;font-size:10pt;">cash equivalents and short-term investments are financial instruments that potentially subject us to concentrations of credit risk. We deposit our cash in financial institutions. At times, such deposits <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> may </div>be in excess of insured limits. We <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> may </div>also invest our excess cash in money market funds, U.S. government agencies, corporate debt securities and commercial paper. We have established guidelines relative to our diversification of our cash investments and their maturities in an effort to maintain safety and liquidity. These guidelines are periodically reviewed and modified to take advantage of trends in yields and interest rates.</div></div> <div style=" font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">&nbsp;</div> <div style=" font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">Sales <div style="display: inline; font-family:Times New Roman, Times, serif;font-size:10pt;">of SUSTOL to <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">two</div> customers accounted for <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">10%</div> or more of our net product sales for the year ended <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December&nbsp;</div><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">31,</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2017.</div> The loss of either of these customers could materially and adversely affect our business, results of operations, financial condition and cash flows. </div></div></div></div></div></div></div></div></div>
CY2017Q4 us-gaap Construction In Progress Gross
ConstructionInProgressGross
2000000
CY2016Q4 us-gaap Construction In Progress Gross
ConstructionInProgressGross
1700000
CY2017Q1 us-gaap Cost Of Goods Sold
CostOfGoodsSold
1186000
CY2017Q2 us-gaap Cost Of Goods Sold
CostOfGoodsSold
1013000
CY2017Q3 us-gaap Cost Of Goods Sold
CostOfGoodsSold
1051000
CY2017Q4 us-gaap Cost Of Goods Sold
CostOfGoodsSold
1338000
CY2016Q1 us-gaap Cost Of Goods Sold
CostOfGoodsSold
CY2016Q2 us-gaap Cost Of Goods Sold
CostOfGoodsSold
CY2016Q3 us-gaap Cost Of Goods Sold
CostOfGoodsSold
CY2016Q4 us-gaap Cost Of Goods Sold
CostOfGoodsSold
35000
CY2017 us-gaap Cost Of Goods Sold
CostOfGoodsSold
4588000
CY2016 us-gaap Cost Of Goods Sold
CostOfGoodsSold
35000
CY2015 us-gaap Cost Of Goods Sold
CostOfGoodsSold
CY2015 us-gaap Debt Instrument Convertible Beneficial Conversion Feature
DebtInstrumentConvertibleBeneficialConversionFeature
328000
CY2016 us-gaap Debt Instrument Convertible Beneficial Conversion Feature
DebtInstrumentConvertibleBeneficialConversionFeature
348000
CY2017 us-gaap Debt Instrument Convertible Beneficial Conversion Feature
DebtInstrumentConvertibleBeneficialConversionFeature
369000
CY2017Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
2763000
CY2016Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
1099000
CY2017Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
172131000
CY2016Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
168890000
CY2017Q4 us-gaap Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
CY2016Q4 us-gaap Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
CY2017Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
134659000
CY2016Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
138727000
CY2017Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
2920000
CY2016Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
3204000
CY2017Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
25919000
CY2016Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
16687000
CY2017Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
8633000
CY2016Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
10272000
CY2017Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
172131000
CY2016Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
168890000
CY2017 us-gaap Defined Contribution Plan Cost Recognized
DefinedContributionPlanCostRecognized
600000
CY2016 us-gaap Defined Contribution Plan Cost Recognized
DefinedContributionPlanCostRecognized
600000
CY2015 us-gaap Defined Contribution Plan Cost Recognized
DefinedContributionPlanCostRecognized
300000
CY2017 us-gaap Defined Contribution Plan Employer Matching Contribution Percent Of Match
DefinedContributionPlanEmployerMatchingContributionPercentOfMatch
0.5
CY2016 us-gaap Defined Contribution Plan Employer Matching Contribution Percent Of Match
DefinedContributionPlanEmployerMatchingContributionPercentOfMatch
0.5
CY2015 us-gaap Defined Contribution Plan Employer Matching Contribution Percent Of Match
DefinedContributionPlanEmployerMatchingContributionPercentOfMatch
0.5
CY2017 us-gaap Depreciation
Depreciation
1500000
CY2016 us-gaap Depreciation
Depreciation
1100000
CY2016 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
21366000
CY2015 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
18395000
CY2017Q1 us-gaap Gross Profit
GrossProfit
2446000
CY2016Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
8414000
CY2017Q4 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
88200000
CY2017 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P3Y
CY2015 us-gaap Depreciation
Depreciation
700000
CY2017 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
1531000
CY2016 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
1099000
CY2015 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
734000
CY2017Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1
CY2017Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.80
CY2017Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.77
CY2017Q4 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.09
CY2016Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.92
CY2016Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.17
CY2016Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.24
CY2016Q4 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.22
CY2017 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-3.65
CY2016 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-4.56
CY2015 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-2.95
CY2017 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.35
CY2017Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
8860000
CY2017 us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
-39000
CY2016 us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
-9000
CY2015 us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
118000
CY2017Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
6742000
CY2017Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
6185000
CY2017Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
6462000
CY2017Q4 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
6165000
CY2016Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
5367000
CY2016Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4774000
CY2016Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
5333000
CY2016Q4 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
5892000
CY2017 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
25554000
CY2015 us-gaap Income Tax Reconciliation Tax Credits Research
IncomeTaxReconciliationTaxCreditsResearch
2757000
CY2017 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
11955000
CY2017Q2 us-gaap Gross Profit
GrossProfit
7497000
CY2017Q3 us-gaap Gross Profit
GrossProfit
7521000
CY2017Q4 us-gaap Gross Profit
GrossProfit
8715000
CY2016Q1 us-gaap Gross Profit
GrossProfit
CY2016Q2 us-gaap Gross Profit
GrossProfit
CY2016Q3 us-gaap Gross Profit
GrossProfit
CY2016Q4 us-gaap Gross Profit
GrossProfit
1244000
CY2017Q1 us-gaap Income Loss From Continuing Operations
IncomeLossFromContinuingOperations
-49299000
CY2017Q2 us-gaap Income Loss From Continuing Operations
IncomeLossFromContinuingOperations
-42055000
CY2017Q3 us-gaap Income Loss From Continuing Operations
IncomeLossFromContinuingOperations
-41314000
CY2017Q4 us-gaap Income Loss From Continuing Operations
IncomeLossFromContinuingOperations
-61890000
CY2016Q1 us-gaap Income Loss From Continuing Operations
IncomeLossFromContinuingOperations
-33312000
CY2016Q2 us-gaap Income Loss From Continuing Operations
IncomeLossFromContinuingOperations
-43066000
CY2016Q3 us-gaap Income Loss From Continuing Operations
IncomeLossFromContinuingOperations
-47734000
CY2016Q4 us-gaap Income Loss From Continuing Operations
IncomeLossFromContinuingOperations
-46803000
CY2017 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2016 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2015 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2017 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
3241000
CY2016 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
55173000
CY2015 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
40445000
CY2017 us-gaap Income Tax Reconciliation Change In Enacted Tax Rate
IncomeTaxReconciliationChangeInEnactedTaxRate
74361000
CY2016 us-gaap Income Tax Reconciliation Change In Enacted Tax Rate
IncomeTaxReconciliationChangeInEnactedTaxRate
CY2015 us-gaap Income Tax Reconciliation Change In Enacted Tax Rate
IncomeTaxReconciliationChangeInEnactedTaxRate
CY2017 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
-67145000
CY2016 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
-58868000
CY2015 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
-33181000
CY2017 us-gaap Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost
IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost
3151000
CY2016 us-gaap Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost
IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost
2694000
CY2015 us-gaap Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost
IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost
894000
CY2017 us-gaap Income Tax Reconciliation Other Reconciling Items
IncomeTaxReconciliationOtherReconcilingItems
-1443000
CY2016 us-gaap Income Tax Reconciliation Other Reconciling Items
IncomeTaxReconciliationOtherReconcilingItems
1330000
CY2015 us-gaap Income Tax Reconciliation Other Reconciling Items
IncomeTaxReconciliationOtherReconcilingItems
352000
CY2017 us-gaap Income Tax Reconciliation State And Local Income Taxes
IncomeTaxReconciliationStateAndLocalIncomeTaxes
-6203000
CY2016 us-gaap Income Tax Reconciliation State And Local Income Taxes
IncomeTaxReconciliationStateAndLocalIncomeTaxes
2013000
CY2015 us-gaap Income Tax Reconciliation State And Local Income Taxes
IncomeTaxReconciliationStateAndLocalIncomeTaxes
-5753000
CY2017 us-gaap Income Tax Reconciliation Tax Credits Research
IncomeTaxReconciliationTaxCreditsResearch
5962000
CY2016 us-gaap Income Tax Reconciliation Tax Credits Research
IncomeTaxReconciliationTaxCreditsResearch
4206000
CY2016 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
3514000
CY2015 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
751000
CY2017 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
39914000
CY2016 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
1960000
CY2015 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
CY2017 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
1664000
CY2016 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
1099000
CY2015 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
CY2017 us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
446000
CY2016 us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
3586000
CY2015 us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
2097000
CY2017 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
4768000
CY2016 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
5340000
CY2015 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
CY2017 us-gaap Increase Decrease In Other Accrued Liabilities
IncreaseDecreaseInOtherAccruedLiabilities
11482000
CY2016 us-gaap Increase Decrease In Other Accrued Liabilities
IncreaseDecreaseInOtherAccruedLiabilities
2482000
CY2015 us-gaap Increase Decrease In Other Accrued Liabilities
IncreaseDecreaseInOtherAccruedLiabilities
1551000
CY2017 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-3000
CY2016 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
338000
CY2015 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
2443000
CY2017 us-gaap Interest Expense
InterestExpense
3937000
CY2016 us-gaap Interest Expense
InterestExpense
2664000
CY2015 us-gaap Interest Expense
InterestExpense
958000
CY2017 us-gaap Interest Paid Net
InterestPaidNet
2789000
CY2016 us-gaap Interest Paid Net
InterestPaidNet
1622000
CY2015 us-gaap Interest Paid Net
InterestPaidNet
CY2017Q4 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
3188000
CY2016Q4 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
2589000
CY2017Q4 us-gaap Inventory Net
InventoryNet
10108000
CY2016Q4 us-gaap Inventory Net
InventoryNet
5340000
CY2017Q4 us-gaap Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
2754000
CY2016Q4 us-gaap Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
1647000
CY2017Q4 us-gaap Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
4166000
CY2016Q4 us-gaap Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
1104000
CY2017 us-gaap Investment Income Interest
InvestmentIncomeInterest
1049000
CY2016 us-gaap Investment Income Interest
InvestmentIncomeInterest
445000
CY2015 us-gaap Investment Income Interest
InvestmentIncomeInterest
174000
CY2017 us-gaap Lease And Rental Expense
LeaseAndRentalExpense
3100000
CY2016 us-gaap Lease And Rental Expense
LeaseAndRentalExpense
2100000
CY2015 us-gaap Lease And Rental Expense
LeaseAndRentalExpense
1500000
CY2017Q3 us-gaap Net Income Loss
NetIncomeLoss
-41866000
CY2017Q4 us-gaap Net Income Loss
NetIncomeLoss
-62490000
CY2016Q1 us-gaap Net Income Loss
NetIncomeLoss
-33445000
CY2016Q2 us-gaap Net Income Loss
NetIncomeLoss
-43226000
CY2016Q3 us-gaap Net Income Loss
NetIncomeLoss
-48509000
CY2016Q4 us-gaap Net Income Loss
NetIncomeLoss
-47963000
CY2017 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-2926000
CY2016 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-2228000
CY2015 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-666000
CY2017Q4 us-gaap Notes Payable Related Parties Classified Current
NotesPayableRelatedPartiesClassifiedCurrent
25000000
CY2016Q4 us-gaap Notes Payable Related Parties Classified Current
NotesPayableRelatedPartiesClassifiedCurrent
CY2017Q4 us-gaap Liabilities
Liabilities
103171000
CY2016Q4 us-gaap Liabilities
Liabilities
88733000
CY2017Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
234307000
CY2016Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
67482000
CY2017Q4 us-gaap Liabilities Current
LiabilitiesCurrent
103171000
CY2016Q4 us-gaap Liabilities Current
LiabilitiesCurrent
38733000
CY2017 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
293731000
CY2016 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
57455000
CY2015 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
137991000
CY2017 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
7738000
CY2016 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
14876000
CY2015 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-56960000
CY2017 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-170300000
CY2016 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-134097000
CY2015 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-78526000
CY2017 us-gaap Net Income Loss
NetIncomeLoss
-197484000
CY2016 us-gaap Net Income Loss
NetIncomeLoss
-173143000
CY2015 us-gaap Net Income Loss
NetIncomeLoss
-97591000
CY2017Q1 us-gaap Net Income Loss
NetIncomeLoss
-50329000
CY2017Q2 us-gaap Net Income Loss
NetIncomeLoss
-42799000
CY2017Q4 us-gaap Notes Payable Related Parties Noncurrent
NotesPayableRelatedPartiesNoncurrent
CY2016Q4 us-gaap Notes Payable Related Parties Noncurrent
NotesPayableRelatedPartiesNoncurrent
50000000
CY2017 us-gaap Operating Expenses
OperatingExpenses
225325000
CY2016 us-gaap Operating Expenses
OperatingExpenses
172194000
CY2015 us-gaap Operating Expenses
OperatingExpenses
96925000
CY2017 us-gaap Operating Income Loss
OperatingIncomeLoss
-194558000
CY2016 us-gaap Operating Income Loss
OperatingIncomeLoss
-170915000
CY2015 us-gaap Operating Income Loss
OperatingIncomeLoss
-96925000
CY2017Q4 us-gaap Operating Leases Future Minimum Payments Due
OperatingLeasesFutureMinimumPaymentsDue
11087000
CY2017Q4 us-gaap Operating Leases Future Minimum Payments Due Current
OperatingLeasesFutureMinimumPaymentsDueCurrent
2418000
CY2017 us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans
989000
CY2017Q4 us-gaap Operating Leases Future Minimum Payments Due In Five Years
OperatingLeasesFutureMinimumPaymentsDueInFiveYears
1590000
CY2017Q4 us-gaap Operating Leases Future Minimum Payments Due In Four Years
OperatingLeasesFutureMinimumPaymentsDueInFourYears
1546000
CY2017Q4 us-gaap Operating Leases Future Minimum Payments Due In Three Years
OperatingLeasesFutureMinimumPaymentsDueInThreeYears
1503000
CY2017Q4 us-gaap Operating Leases Future Minimum Payments Due In Two Years
OperatingLeasesFutureMinimumPaymentsDueInTwoYears
1906000
CY2017Q4 us-gaap Operating Leases Future Minimum Payments Due Thereafter
OperatingLeasesFutureMinimumPaymentsDueThereafter
2124000
CY2017Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
17175000
CY2016Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
6288000
CY2017Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
263000
CY2016Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
263000
CY2015 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-40000
CY2016 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
23000
CY2017 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
7000
CY2017Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-1030000
CY2017Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-744000
CY2017Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-552000
CY2017Q4 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-600000
CY2016Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-133000
CY2016Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-160000
CY2016Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-775000
CY2016Q4 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-1160000
CY2017 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-38000
CY2016 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-9000
CY2015 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
118000
CY2017Q4 us-gaap Other Sundry Liabilities Current
OtherSundryLiabilitiesCurrent
188000
CY2016Q4 us-gaap Other Sundry Liabilities Current
OtherSundryLiabilitiesCurrent
88000
CY2017 us-gaap Payments To Acquire Available For Sale Securities
PaymentsToAcquireAvailableForSaleSecurities
121570000
CY2016 us-gaap Payments To Acquire Available For Sale Securities
PaymentsToAcquireAvailableForSaleSecurities
43318000
CY2015 us-gaap Payments To Acquire Available For Sale Securities
PaymentsToAcquireAvailableForSaleSecurities
56115000
CY2017 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
2553000
CY2016 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
3135000
CY2015 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
1086000
CY2017Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2016Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2017Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
2500
CY2016Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
2500
CY2017Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2016Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2017Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2016Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2017Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2016Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2017Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
3702000
CY2016Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
3705000
CY2011Q2 us-gaap Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
4300000
CY2017Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
163700000
CY2017Q4 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
142600000
CY2016 us-gaap Proceeds From Related Party Debt
ProceedsFromRelatedPartyDebt
50000000
CY2015 us-gaap Proceeds From Related Party Debt
ProceedsFromRelatedPartyDebt
CY2017 us-gaap Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
131783000
CY2017 us-gaap Proceeds From Related Party Debt
ProceedsFromRelatedPartyDebt
CY2016 us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans
771000
CY2015 us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans
257000
CY2017 us-gaap Proceeds From Issuance Or Sale Of Equity
ProceedsFromIssuanceOrSaleOfEquity
306279000
CY2016 us-gaap Proceeds From Issuance Or Sale Of Equity
ProceedsFromIssuanceOrSaleOfEquity
CY2015 us-gaap Proceeds From Issuance Or Sale Of Equity
ProceedsFromIssuanceOrSaleOfEquity
128199000
CY2016 us-gaap Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
61329000
CY2015 us-gaap Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
CY2017 us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
78000
CY2016 us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
CY2015 us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
241000
CY2017 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
11463000
CY2016 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
6684000
CY2015 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
9535000
CY2017Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
13840000
CY2016Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
11690000
CY2017Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
5981000
CY2016Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
5076000
CY2017 us-gaap Property Plant And Equipment Useful Life
PropertyPlantAndEquipmentUsefulLife
P5Y
CY2017Q4 us-gaap Purchase Obligation
PurchaseObligation
39700000
CY2017 us-gaap Repayments Of Long Term Debt
RepaymentsOfLongTermDebt
25000000
CY2016 us-gaap Repayments Of Long Term Debt
RepaymentsOfLongTermDebt
CY2015 us-gaap Repayments Of Long Term Debt
RepaymentsOfLongTermDebt
CY2017Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
33384000
CY2017Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
28597000
CY2017Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
28844000
CY2017Q4 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
47757000
CY2016Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
16092000
CY2016Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
27286000
CY2016Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
30242000
CY2016Q4 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
29505000
CY2017 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
138582000
CY2016 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
103125000
CY2015 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
61183000
CY2017Q4 us-gaap Restructuring And Related Cost Expected Cost1
RestructuringAndRelatedCostExpectedCost1
9600000
CY2017Q4 us-gaap Restructuring Reserve Current
RestructuringReserveCurrent
1086000
CY2016Q4 us-gaap Restructuring Reserve Current
RestructuringReserveCurrent
2704000
CY2017Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-783455000
CY2016Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-585971000
CY2017Q1 us-gaap Sales Revenue Goods Net
SalesRevenueGoodsNet
3632000
CY2017Q2 us-gaap Sales Revenue Goods Net
SalesRevenueGoodsNet
8510000
CY2017Q3 us-gaap Sales Revenue Goods Net
SalesRevenueGoodsNet
8572000
CY2017Q4 us-gaap Sales Revenue Goods Net
SalesRevenueGoodsNet
10053000
CY2016Q1 us-gaap Sales Revenue Goods Net
SalesRevenueGoodsNet
CY2016Q2 us-gaap Sales Revenue Goods Net
SalesRevenueGoodsNet
CY2016Q3 us-gaap Sales Revenue Goods Net
SalesRevenueGoodsNet
CY2016Q4 us-gaap Sales Revenue Goods Net
SalesRevenueGoodsNet
1279000
CY2017 us-gaap Sales Revenue Goods Net
SalesRevenueGoodsNet
30767000
CY2016 us-gaap Sales Revenue Goods Net
SalesRevenueGoodsNet
1279000
CY2015 us-gaap Sales Revenue Goods Net
SalesRevenueGoodsNet
CY2017Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
4685432
CY2017Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
5446586
CY2016Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
4356665
CY2015Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
2587392
CY2017Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
13.25
CY2015 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
10.42
CY2016 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
22.43
CY2017Q1 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
11619000
CY2017Q2 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
14770000
CY2017Q3 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
13529000
CY2017Q4 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
16683000
CY2016Q1 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
11853000
CY2016Q2 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
11006000
CY2016Q3 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
12159000
CY2016Q4 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
12650000
CY2017 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
56601000
CY2016 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
47668000
CY2015 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
17347000
CY2017 us-gaap Share Based Compensation
ShareBasedCompensation
30538000
CY2016 us-gaap Share Based Compensation
ShareBasedCompensation
25956000
CY2015 us-gaap Share Based Compensation
ShareBasedCompensation
14360000
CY2017 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Period1
ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
P4Y
CY2016Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
11.66
CY2015Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
8.72
CY2017 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
9900000
CY2016 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
10400000
CY2017 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
338509
CY2015 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
575178
CY2016 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
711910
CY2017 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
1332429
CY2017 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
20.06
CY2017 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
993920
CY2015 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
2134505
CY2016 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
4920661
CY2017 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
4300621
CY2017Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
35600000
CY2016Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
16900000
CY2017Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
13462963
CY2014Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
7918004
CY2015Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
8434988
CY2016Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
11845376
CY2014Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
8.69
CY2015Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
13.64
CY2016Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
14.44
CY2017Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
15.03
CY2017 us-gaap Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Lower Range Limit
ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit
5.20
CY2017Q4 us-gaap Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Exercisable Options
ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
5446586
CY2017Q4 us-gaap Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Outstanding Options
ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
13462963
CY2017 us-gaap Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Upper Range Limit
ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
38.46
CY2017Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
12854571
CY2016Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
11234529
CY2015Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
8059481
CY2017Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
14.98
CY2016Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
14.32
CY2015Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
13.38
CY2015 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
9.15
CY2016 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
8.37
CY2017 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
8.49
CY2017 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
26.81
CY2017 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
17.77
CY2015 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
28.95
CY2016 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
15.98
CY2017 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
16.17
CY2017 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Expiration Period
SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
P10Y
CY2017Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
35600000
CY2016Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
16900000
CY2017 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P6Y182D
CY2017Q4 us-gaap Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Exercisable Options Weighted Average Exercise Price1
SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1
13.25
CY2017Q4 us-gaap Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Exercise Price Beginning Balance1
SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1
15.03
CY2017 us-gaap Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Remaining Contractual Term2
SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2
P8Y3D
CY2015 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
1042343
CY2016 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
798363
CY2017 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
1350605
CY2015 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
257000
CY2016 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
771000
CY2017 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
989000
CY2015 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
128199000
CY2017 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
306279000
CY2015 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
9535000
CY2016 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
6684000
CY2017 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
11463000
CY2017Q4 us-gaap Stockholders Equity
StockholdersEquity
131136000
CY2016Q4 us-gaap Stockholders Equity
StockholdersEquity
-21251000
CY2014Q4 us-gaap Stockholders Equity
StockholdersEquity
63062000
CY2015Q4 us-gaap Stockholders Equity
StockholdersEquity
118110000
CY2016Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
100000
CY2017Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
100000
CY2016Q4 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
0
CY2017Q4 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
0
CY2016Q4 us-gaap Unrecognized Tax Benefits That Would Impact Effective Tax Rate
UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate
100000
CY2017Q4 us-gaap Unrecorded Unconditional Purchase Obligation Balance Sheet Amount
UnrecordedUnconditionalPurchaseObligationBalanceSheetAmount
35900000
CY2017 us-gaap Use Of Estimates
UseOfEstimates
<div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:left;"><div style="display: inline; font-style: italic;"><div style="display: inline; font-weight: bold;">Use of Estimates</div></div></div> <div style=" font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</div> <div style=" font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">The preparation of financial statements in conformity with accounting principles generally accepted in the <div style="display: inline; font-family:Times New Roman, Times, serif;font-size:10pt;">U.S. requires management to make estimates and assumptions that affect the amounts reported in the financial statements and disclosures made in the accompanying notes to the financial statements. Our critical accounting policies that involve significant judgment and estimates include revenue recognition, inventory, accrued clinical liabilities, income taxes and stock-based compensation. Actual results could differ materially from those estimates.</div></div></div></div></div></div></div></div></div>
CY2016Q4 us-gaap Valuation Allowances And Reserves Balance
ValuationAllowancesAndReservesBalance
342000
CY2017Q4 us-gaap Valuation Allowances And Reserves Balance
ValuationAllowancesAndReservesBalance
9319000
CY2017 us-gaap Valuation Allowances And Reserves Deductions
ValuationAllowancesAndReservesDeductions
10275000
CY2017 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
54040000
CY2016 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
37925000
CY2015 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
33081000

Files In Submission

Name View Source Status
0001193125-18-060951-index-headers.html Edgar Link pending
0001193125-18-060951-index.html Edgar Link pending
0001193125-18-060951.txt Edgar Link pending
0001193125-18-060951-xbrl.zip Edgar Link pending
d530534d10k.htm Edgar Link pending
d530534dex231.htm Edgar Link pending
d530534dex311.htm Edgar Link pending
d530534dex312.htm Edgar Link pending
d530534dex321.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
g530534g55s30.jpg Edgar Link pending
hrtx-20171231.xml Edgar Link completed
hrtx-20171231.xsd Edgar Link pending
hrtx-20171231_cal.xml Edgar Link unprocessable
hrtx-20171231_def.xml Edgar Link unprocessable
hrtx-20171231_lab.xml Edgar Link unprocessable
hrtx-20171231_pre.xml Edgar Link unprocessable
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending